ALKERMES | ALKS - 普通股股本

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.59B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	普通股股本	更改		日
AbbVie	USD 1.77B		1.75B	2025-06
Acadia Pharmaceuticals	USD 171.09M		1.9M	2026-03
ALKERMES	USD 167.54M		1.08M	2026-06
Amgen	USD 541M		1000K	2026-06
Biogen	USD 146.7M		200K	2025-09
BioMarin Pharmaceutical	USD 193.54M		267K	2026-06
Bristol-Myers Squibb	USD 2.04B		1.74B	2025-09
Coherus Biosciences	USD 121.16M		4.92M	2025-12
Eli Lilly	USD 943.5M		3.33M	2026-03
Gilead Sciences	USD 1.24B		1000K	2026-06
Heron Therapeutics	USD 188.31M		4.99M	2025-12
Ionis Pharmaceuticals	USD 165.64M		265K	2026-06
J&J	USD 2.41B		1.35M	2026-03
Malin Corporation	EUR 200K		0	2024-12
Merck	USD 2.47B		4.93M	2026-03
Minerva Neurosciences	USD 1000		0	2024-09
Nektar Therapeutics	USD 29.47M		9.09M	2026-03
Neurocrine Biosciences	USD 100.55M		50K	2026-06
Otsuka Holdings	JPY 525.39M		1.91M	2026-06
Ovoca Bio	EUR 29.49M		0	2025-12
Pfizer	USD 5.7B		0	2026-06
Regeneron Pharmaceuticals	USD 105M		300K	2026-03
Vertex Pharmaceuticals	USD 253.3M		900K	2026-06